Loss of heterozygosity on chromosome 19 in secondary glioblastomas

被引:109
作者
Nakamura, M
Yang, F
Fujisawa, H
Yonekawa, Y
Kleihues, P
Ohgaki, H
机构
[1] Int Agcy Res Canc, Unit Mol Pathol, F-69372 Lyon 08, France
[2] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland
关键词
LOH on chromosome 19; primary glioblastoma; secondary glioblastoma;
D O I
10.1093/jnen/59.6.539
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastomas develop rapidly de novo (primary glioblastomas) or slowly through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). Recent studies have shown that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR amplification/overexpression, PTEN mutation, homozygous p16 deletion, and loss of heterozygosity (LOH) on entire chromosome 10, whereas secondary glioblastomas frequently contain p53 mutations and show LOH on chromosome 10q. In this study, we analyzed LOH on chromosomes 19q, 1p, and 13q, using polymorphic microsatellite markers in 17 primary glioblastomas and in 13 secondary glioblastomas that progressed from low-grade astrocytomas. LOH on chromosome 19q was frequently found in secondary glioblastomas (7 of 13, 54%) but rarely detected in primary glioblastomas (1 of 17, 6%, p = 0.0094). The common deletion was 19q13.3 (between D19S219 and D19S902). These results suggest that tumor suppressor gene(s) located on chromosome 19q are frequently involved in the progression from low-grade astrocytoma to secondary glioblastoma, but do not play a major role in the evolution of primary glioblastomas. LOH on chromosome 1p was detected in 12% of primary and 15% of secondary glioblastomas. LOH on 13q was detected in 12% of primary and in 38% of secondary glioblastomas and typically included the RE locus. Except for 1 case, LOH 13q and 19q were mutually exclusive.
引用
收藏
页码:539 / 543
页数:5
相关论文
共 50 条
[1]   MOLECULAR ANALYSIS OF CHROMOSOME-1 ABNORMALITIES IN HUMAN GLIOMAS REVEALS FREQUENT LOSS OF 1P IN OLIGODENDROGLIAL TUMORS [J].
BELLO, MJ ;
VAQUERO, J ;
DECAMPOS, JM ;
KUSAK, ME ;
SARASA, JL ;
SAEZCASTRESANA, J ;
PESTANA, A ;
REY, JA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) :172-175
[2]   ALLELIC STATUS OF CHROMOSOME-1 IN NEOPLASMS OF THE NERVOUS-SYSTEM [J].
BELLO, MJ ;
LEONE, PE ;
NEBREDA, P ;
DECAMPOS, JM ;
KUSAK, ME ;
VAQUERO, J ;
SARASA, JL ;
GARCIAMIGUEL, P ;
QUEIZAN, A ;
HERNANDEZMONEO, JL ;
PESTANA, A ;
REY, JA .
CANCER GENETICS AND CYTOGENETICS, 1995, 83 (02) :160-164
[3]   Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas [J].
Biernat, W ;
Tohma, Y ;
Yonekawa, Y ;
Kleihues, P ;
Ohgaki, H .
ACTA NEUROPATHOLOGICA, 1997, 94 (04) :303-309
[4]   TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95) [J].
Bodmer, JL ;
Burns, K ;
Schneider, P ;
Hofmann, K ;
Steiner, V ;
Thome, M ;
Bornand, T ;
Hahne, M ;
Schroter, M ;
Becker, K ;
Wilson, A ;
French, LE ;
Browning, JL ;
MacDonald, HR ;
Tschopp, J .
IMMUNITY, 1997, 6 (01) :79-88
[5]  
BRUSTLE O, 1992, CANCER, V69, P2385, DOI 10.1002/1097-0142(19920501)69:9<2385::AID-CNCR2820690929>3.0.CO
[6]  
2-3
[7]   Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas [J].
Burns, KL ;
Ueki, K ;
Jhung, SL ;
Koh, J ;
Louis, DN .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (02) :122-130
[8]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[9]   The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas [J].
Chou, D ;
Miyashita, T ;
Mohrenweiser, HW ;
Ueki, K ;
Kastury, K ;
Druck, T ;
vonDeimling, A ;
Huebner, K ;
Reed, JC ;
Louis, DN .
CANCER GENETICS AND CYTOGENETICS, 1996, 88 (02) :136-140
[10]  
COLLINS N, 1995, ONCOGENE, V10, P1673